Changes in Beneficial Ownership · 4
Amylyx Pharmaceuticals, Inc.
AMLXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-10
- Issuer
- Amylyx Pharmaceuticals, Inc.
- Issuer CIK
- 0001658551
- Trading symbol
- AMLX
Reporting owner 1
- Name
- FRATES JAMES M
- Reporting owner CIK
- 0001235598
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O AMYLYX PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-10 | S · Form 4[F1] | 9,768 | D | 32.2681[F2] | 234,667 | D |
| Common Stock | 2026-09-10 | S · Form 4[F1] | 1,042 | D | 33.2302[F3] | 233,625 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 100,000 | I | By Trust[F4] |
| Common Stock | 15,459 | I | By Trust[F5] |
| Common Stock | 11,072 | I | By Trust[F6] |
| Common Stock | 40,000 | I | By Trust[F7] |
Table key
- I
- Indirect
Footnotes
- F1
- Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.↩ 1↩ 2
- F2
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.805 to $32.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.↩ 1
- F3
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $33.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.↩ 1
- F4
- Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.↩ 1
- F5
- Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.↩ 1
- F6
- Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.↩ 1
- F7
- Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.↩ 1
Signature 1
- Signed
- /s/ Joshua B. Cohen, as Attorney in Fact
- Date
- 2026-09-14
Company context
At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.